We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Podcast Radio (PR) is the Ofcom-licensed UK digital broadcast radio station showcasing podcasts 24/7 globally. It is currently broadcasting in Surrey, Manchester, London, and Glasgow. Podcasting is expected to become a $3.3 billion industry by 2025. PR aims to be a disruptor in this segment. PR got front-page coverage in the international edition of Radio World magazine and has onboarded US radio Disc Jockey (DJ) Gene Baxter. The company will use 15% of the investment to secure digital radio broadcast transmission in 5 more UK cities by the end of 2020, 15% to partner with applicants for new digital radio transmitters, 15% to create a PR-led UK marketing campaign supported by social media, 25% to recruit new staff members, 10% to develop its on-air content, 10% to develop its website and application, and 10% to build new business partnerships to drive the international expansion of the company.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £149,023
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £1,036,436
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £134,892
Advanced Blast & Ballistic Systems (ABBS) is a company that has developed globally patented systems to counteract the forces an armoured vehicle sustains when a mine or Improvised Explosive Device (IED) explodes under it. As per reports, mines and IEDs accounted for over 80% of UK and US army casualties in Iraq & Afghanistan. ABBS believes that its products can keep occupants inside a vehicle completely safe from the aforementioned explosive devices. The armoured vehicle protection market has a value of about $20 billion wherein ABBS aims to be a major contender. The company has received £2 million-plus revenues till date from Research and Development (R&D) grants in the UK, as well as, sold its products to the US Army and Israel with profits worth £145,000 in 2018 and £560,000 in 2019 respectively. It will use the investment to bring its products to more markets globally.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £445,814
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £532,311
Antaco is a company that deals in waste management by converting it into neutral solid biofuel using their patented technology. The global water sector is estimated to present a £15 billion opportunity. To date, the company has raised £5.8 million, including an £857,000 grant from the UK government and has also signed a contract with its first customer (Swiss Public Utility). With the proceeds, the company will build up their in-house capacity, increase enhancement of existing plant and hire subcontractors to install and commission plant.

Pitch Rated

77%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £570,840
Jeeni is an online entertainment service that aims to harness the growing reach of streamed music. It has close to 350 million subscribers and a growth rate of 39% Year-on-Year (YoY) providing billion-dollar revenues for digital disruptors. The Jeeni prototype was launched in April 2019. The company asserts that it offers artists an ethical revenue share. Five revenue streams are operating in parallel on the Jeeeni platform, namely, subscription-based memberships, online masterclasses, bespoke hardware sales, pay-to-view streamed events, and branded merchandise sales. The company's long term goal is to surpass its target paid subscriber numbers, achieve high subscriber growth and exit by acquisition. The investment raised will be used to further scale the company's capacity globally and build its mass artist showcases.

Pitch Rated

77%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £118,854
Creative Hub is a fast-growing cloud software platform for creative people to store, share files, and collaborate on projects. The collaboration tools also allow users to chat in real-time, and add comments on images, allowing creative teams to work faster and deliver better results. Creative Hub enables users to order professional art & photographic prints, or physical 3D prints, which are produced at its print production facilities in London(UK) and Dusseldorf (Germany). The platform currently has 40,000 active users which are growing day by day. With the investment, the company will drive growth through marketing and launch its New York production facility.

Pitch Rated

76%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £286,992
Rightangled is a DNA testing company backed by NHS that delivers services to consumers and medical/fitness specialists. The company is a full CQC healthcare provider license that has achieved registration with Bupa, a leading medical insurance company. The company is now planning to move into AI with a solid database. Rightangled has received excellent customer reviews with 5* on Google and 4.5* on Trustpilot. With the proceeds, the company will seek to launch its application, create a strong AI central system, and grow into new markets (US& UAE).

Pitch Rated

75%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £311,690
Sol-Gel Materials and Application (SGMA) is a sustainable technology company that is using its new sol-gels to create sustainable solutions to plastic environmental waste. The company has researched and developed a non-plastic, non-toxic coating for products, from food packaging to electronics, that is water and oil resistant yet recyclable. Its product is the world’s only biodegradable, compostable, and recyclable (BCR) solution. The company's founder and CEO, Dr Fanya Ismail, has won the award 'Women in Innovation 2019' by Innovate UK and the company's work has been covered by BBC South East Today. The company plans to function as an IP management company, sub-contract manufacturing to chemical firms moving from bulk to advanced materials, and outsource distribution to partners, whose packaging customers serve brand owners.

Pitch Rated

72%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £611,040
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph